News Focus
News Focus
Followers 43
Posts 5340
Boards Moderated 0
Alias Born 12/05/2021

Re: Hopeforthefuture3 post# 730032

Monday, 11/04/2024 3:19:49 AM

Monday, November 04, 2024 3:19:49 AM

Post# of 819922
mmmmm

DCVAXL trial
Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months

SurVaxM is an experimental vaccine for the treatment of brain tumors. Early results from a small trial were recently reported Of 63 patients with newly diagnosed Glioblastoma, the median overall survival was 25.9 months from the first dose of the vaccine,

and not a personalized vaccine so easier to produce
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News